Physician profile
Indraneil Ray
NPI 1760641013
$1,790.27
in general payments reported to CMS, 2019-2025
10 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.73 · 2020: $126 · 2021: $383 · 2022: $730 · 2023: $233 · 2024: $77.99 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $965.21 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $245.78 | 2020-2024 | Lifevest |
| Impulse Dynamics (USA) INC. | $194.75 | 2023 | Optimizer |
| Abbott Laboratories | $157.17 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Janssen Pharmaceuticals, INC | $78.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $57.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.91 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $24.01 | 2019 | |
| Boston Scientific Corporation | $18.19 | 2023 | Varithena Administration Pack |
| Portola Pharmaceuticals, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indraneil Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.